期刊
ADVANCES IN NUTRITION
卷 12, 期 2, 页码 533-545出版社
OXFORD UNIV PRESS
DOI: 10.1093/advances/nmaa120
关键词
bovine colostrum; inflammatory bowel disease; IBD; treatment; gastrointestinal; cytokines; immunoglobulins
资金
- Medical University of Lodz [503/1-156-04/503-11-001-19-00]
Inflammatory bowel disease is a group of chronic relapsing disorders with insufficient available therapeutic approaches; current treatment strategies target immune system dysfunctions, with auxiliary therapies involving personalized diet and healthy lifestyle.
Inflammatory bowel disease (IBD) is a group of chronic relapsing disorders whose etiology has not been fully explained. Therefore, available therapeutic approaches for IBD patients are still insufficient. Current treatment strategies are targeted to immune system dysfunctions, often associated with alternations in the microbiota, which contribute to the development of chronic intestinal inflammation. Therapeutics include anti-inflammatory drugs such as aminosalicylates and corticosteroids, immunosuppressive agents, antibiotics, and biological agents such as infliximab and vedolizumab. Auxiliary therapies involve a balanced and personalized diet, healthy lifestyle, avoiding stress, as well as dietary supplements. In this review, we discuss the use of bovine colostrum (BC) as a therapeutic agent, including its advantages and contraindications. We summarize our knowledge on well-researched BC constituents and their effects on the gastrointestinal tract as evidenced in in vitro and in vivo studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据